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Abstract
The proteasomes of some protozoa are possible targets for chemotherapy. Leishmaniasis is a major health problem in human
immunodeficiency virus (HIV) co-infected subjects. Two HIV protease inhibitors (PI), indinavir and saquinavir, have been shown to block
proteasome functions; we therefore investigated their effects on the growth of two Leishmania spp. (Leishmania major and Leishmania
infantum). After 24 h of treatment, both drugs exhibited a dose-dependent antileishmanial activity, with 50% lethal dose (LD50) values of,
respectively, 8.3M and 7M on L. major; minor activity was observed on L. infantum. These results add new in vitro insights into the
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dide-spectrum efficacy of PI and suggest studying their action on amastigote forms of leishmania within macrophages in order to validate
heir potential contribution against opportunistic infections in treated seropositive patients.
2005 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
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. Introduction
Leishmaniasis currently affects an estimated 12 million
eople, in every continent except Australia and Antarctica.
oreover, the emergence of visceral leishmaniasis as an
pportunistic infection [1], particularly in patients infected
ith human immunodeficiency virus (HIV), has given rise
o the need for new therapeutic strategies. The control of
eishmania infection is T-cell dependent and requires a Th1
esponse. There has therefore been an increased incidence
f kala azar in HIV co-infected patients in Bihar (India) [2],
nd in the Mediterranean basin up to 9% of acquired immune
eficiency syndrome (AIDS) patients suffer from newly
cquired or reactivated visceral leishmaniasis [3]. Treatment
ith antimonials, the mainstay of therapy, is less satisfactory
n immunocompromised patients than in immunocompetent
ubjects [1]. New therapies, such as lipid formulations of
mphotericin B or miltefosine, are very expensive. There-
ore, there is a pressing need for new antileishmanial drugs.
he incidence of HIV–Leishmania co-infections has been
∗
decreasing since the introduction of highly active antiretro-
viral therapy (HAART) [4,5]. Some antiretroviral agents
exhibit significant inhibitory effects on purified human
proteasome functions [6,7]. In recent years several studies
have documented the antiprotozoal activity of some pro-
teasome inhibitors. Proteasomes are large, non-lysosomal,
multi-subunit protease complexes. They are characterised
by evolutionarily conserved proteins and are present in Try-
panosoma brucei [8], Trypanosoma cruzi [9], Toxoplasma
gondii [10], Plasmodium spp. [11], Entamoeba histolytica
and Entamoeba invadens [12], as well as in Leishmania
mexicana [13]. A molecular similarity was found between
the human 20S proteasome -type subunit and a Leishmania
donovani cDNA clone [14] and between a gene encoding a
20S proteasome  subunit in Plasmodium falciparum [15].
Proteasomes play a key role in differentiation and replication
of protozoa, and lactacystin, a specific inhibitor of protea-
somes, has a negative impact on the replication ofL.mexicana
promastigotes, although only at a high concentration [13].
We explored whether indinavir and saquinavir, two
HIV protease inhibitors (PI) commonly used in infected
individuals that share potent inhibitory effects on purifiedCorresponding author. Tel.: +39 011 670 5427; fax: +39 011 903 8639.
E-mail address: dianella.savoia@unito.it (D. Savoia). human proteasomes [6,7], have antileishmanial activity.
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The activity of dl--difluoromethylornithine (DFMO),
a polyamine analogue inhibiting protozoon ornithine
decarboxylase [16], was also assessed.
2. Materials and methods
2.1. Leishmaniae
Leishmania major (LRC-L137 strain) and Leishmania
infantum (MHOM/TN/80/IPT1 strain) were maintained in
vitro at 25 ◦C in Tobie’s diphasic medium. Before use, pro-
mastigotes were grown in medium 199 (Invitrogen, CA,
USA), modified as previously indicated [17], at 25 ◦C for
4 days to reach late-log phase growth.
2.2. In vitro studies
The effects of the two PI, indinavir (Merck; a kind gift
of S. Vella, Rome, Italy) and saquinavir (BS 00120083; a
kind gift of Roche, Basel, Switzerland), on promastigotes of
L. major and L. infantum were assessed by a method sim-
ilar to that previously described [17]. Promastigotes were
counted using a haemocytometer (Thoma chamber) and re-
suspended in fresh medium to a final concentration of 5× 105
viable (showing motile behaviour and/or lack of staining
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standard deviations were ≤10% of the means obtained at
each point. The 50% lethal dose (LD50), i.e. the drug con-
centration that caused a 50% reduction in survival/viability
in comparison with that in identical cultures without the com-
pound, was evaluated after 24 h. This value was determined
by non-linear regression analysis, by plotting the number of
viable promastigotes versus log drug concentrations by use
of GraphPad Prism 3 software.
3. Results and discussion
The results demonstrate that after 1 day of treatment,
starting from a concentration of 6.25M, both indinavir
and saquinavir induced ∼50% growth inhibition of L. major
promastigotes (Table 1). At this time point, DMSO also
exhibited a mild inhibitory activity, although only at dilu-
tions corresponding to a drug concentration of≥25M. After
2 days (and likewise after 3 days), the inhibitory effects of
saquinavir on parasite growth persisted, ranging from 17%
to 65% inhibition in a dose-dependent manner (Table 1).
Similar results were obtained with indinavir, although the
range of the inhibitory effect was lower. Conversely, at these
time points the inhibition by DMSO virtually disappeared
(Table 1). The antileishmanial activity was irreversible, and
protozoa did not resume growth when subcultured in fresh
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I e dilutifter vital staining with trypan blue) promastigotes/mL. The
wo compounds were added to the cultures at final con-
entrations of 6.25, 12.5, 25 and 50M (starting from a
mM solution in dimethylsulfoxide (DMSO) that was seri-
lly diluted in medium). Dilutions of DMSO corresponding
o those used to prepare the drug solutions were assessed
n parallel. dl--DFMO (Sigma, Milan, Italy) was assayed
t final concentrations of 3, 6, 12 and 24 mM. After 24, 48
nd 72 h incubation at 25 ◦C with occasional agitation, the
umber of viable, motile promastigotes was quantified. At
he end of 24 h incubation, the reversibility of the effect was
ssessed by adding fresh complete medium at a 10:1 ratio;
he same dilution was made for the control. After a further
8 h incubation, the number of live promastigotes was eval-
ated. The experiments were performed in triplicate and the
able 1
ffect of indinavir and saquinavir on the in vitro growth of L. major and L
edium (considered 100%)
eishmania spp. Days of treatment Dose
50M 25
I S D I
. major 1 35a 35a 60 38a
2 47a 35a 71 66
3 48a 45a 83 78
. infantum 1 69 66 94 72
2 72 68 94 80
3 71 66 96 80
, indinavir; S, saquinavir; D, dimethylsulfoxide (DMSO) control at the sam
a Statistically significant difference, P< 0.05.edium. After incubation for 24 h, the LD50 values of indi-
avir and saquinavir were 8.3± 0.9M and 7± 0.7M,
espectively. The inhibitory and lethal effects of the drugs
n the L. infantum yield were less evident (Table 1), rang-
ng from 5% to 34% in a dose-dependent manner. DMSO
xhibited a limited inhibitory activity at higher concentra-
ions (LD50 values >50M for both protozoa). dl--DFMO
lso had leishmanicidal effects, although only at high con-
entrations (LD50 of 6 mM for L. major and 15 mM for L.
nfantum), higher than those values found on L. donovani
18].
Our findings demonstrate that indinavir and saquinavir
ave a dose-dependent leishmanicidal activity in vitro, which
s greater on L. major than on L. infantum promastigotes.
he inhibition of leishmanial growth produced by these com-
um promastigotes: values are reported as percentages of control grown in
12.5M 6.25M
D I S D I S D
7a 72 43a 41a 100 53 51 100
60 88 80 71 100 93 80 100
58 95 85 77 100 100 83 100
70 95 88 80 100 90 88 100
75 95 88 83 100 95 93 100
75 100 90 85 100 95 90 100
on used for drug solutions.
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pounds may be due to their effects on proteasome activity. As
observed on L. mexicana [13], these effects may depend on
the stage of the parasite; for example, amastigotes develop-
ing within macrophages during human infection are more
sensitive to lactacystin than promastigotes developing in cul-
ture medium. If the same applies to indinavir and saquinavir,
their leishmanicidal effects should be higher in vivo than
in vitro. Potent antiretroviral therapy with PI decreases the
expression of virulence enzymes of Candida albicans [19];
furthermore, it has a negative impact on the yield of Cryp-
tococcus neoformans [20], Pneumocystis carinii [21] and
Cryptosporidium parvum [22]. In addition to the immune
restoration, HIV-infected patients receiving PI may thus ben-
efit from their direct inhibitory activity on a large array of
microorganisms.
These results add new in vitro insights into the wide-
spectrum efficacy of HIV PI and suggest studying their action
on amastigote forms of leishmania within macrophages to
validate their potential contribution against opportunistic
infections in treated seropositive patients.
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